Blastic plasmacytoid dendritic cell neoplasm: A rapidly progressive and fatal disease without aggressive intervention

5Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive myeloid neoplasm derived from plasmacytoid monocytes. The most common presentation involves cutaneous manifestations, which are often accompanied by bone marrow involvement. The tumor cells reveal an immature blastic appearance and diagnosis is based on the expression of cluster of differentiation (CD)4 and CD56. The literature reports a high relapse rate and poor prognosis when treated with leukemia-type induction chemotherapy alone; however, long-term remission is attainable with allogeneic stem cell transplantation in the frst complete remission. Here, we report the dismal course of a patient with BPDCN with cutaneous and bone marrow involvement unable to undergo an aggressive intervention. © the author(s), publisher and licensee Libertas Academica Ltd.

Cite

CITATION STYLE

APA

Prochaska, L., Dakhil, C., & Mathur, S. (2013). Blastic plasmacytoid dendritic cell neoplasm: A rapidly progressive and fatal disease without aggressive intervention. Clinical Medicine Insights: Case Reports, 6, 201–204. https://doi.org/10.4137/ccrep.s12608

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free